Compare INTT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | GNLX |
|---|---|---|
| Founded | 1981 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.2M | 110.4M |
| IPO Year | 1997 | 2022 |
| Metric | INTT | GNLX |
|---|---|---|
| Price | $11.41 | $2.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.50 | ★ $17.25 |
| AVG Volume (30 Days) | 108.2K | ★ 297.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,801,000.00 | $8,000.00 |
| Revenue This Year | $15.82 | N/A |
| Revenue Next Year | $9.10 | N/A |
| P/E Ratio | $193.67 | ★ N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $7.07 | $2.29 |
| 52 Week High | $20.00 | $8.54 |
| Indicator | INTT | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 38.62 |
| Support Level | $10.32 | $2.33 |
| Resistance Level | $14.90 | $2.97 |
| Average True Range (ATR) | 0.51 | 0.16 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 41.62 | 11.61 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.